Translational and regulatory challenges for exon skipping therapies

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Antisense oligonucleotide (AON)-mediated exon skipping is a promising therapeutic strategy for rare genetic diseases.
• Translational development of AONs faces challenges unique to rare diseases and the AON approach itself.

Purpose of the Study:

• To outline key outcomes from a workshop focused on advancing AON-mediated exon skipping therapies for rare diseases.
• To address translational challenges in preclinical development, clinical trial design, and regulatory strategies.

Main Methods:

• A workshop convened experts from patient organizations, academia, and regulatory bodies (European Medicines Agency, Medicine Evaluation Board).
• Discussions focused on preclinical development, trial design, outcome measures, and marketing authorization pathways.

Main Results:

• Identified challenges include small patient populations, limited natural history data, and defining clinical outcome measures for rare diseases.
• Specific AON-related challenges include limited long-term safety data and the need for mutation-specific AON development.
• Key outcomes address strategies for preclinical development, robust trial design, and appropriate regulatory pathways.

Conclusions:

• Addressing translational hurdles is crucial for the successful clinical application of AON-mediated exon skipping in rare diseases.
• Collaborative efforts between researchers, patients, and regulatory agencies are essential to overcome development challenges.